EF Hutton Initiates Coverage On CARISMA Therapeutics With Buy Rating, Announces Price Target of $24
EF Hutton Initiates Coverage On CARISMA Therapeutics With Buy Rating, Announces Price Target of $24
EF Hutton發佈買入評級,宣佈CARISMA Therapeutics的目標股價爲24美元
EF Hutton analyst Jason Kolbert initiates coverage on CARISMA Therapeutics (NASDAQ:CARM) with a Buy rating and announces Price Target of $24.
EF Hutton的分析師Jason Kolbert對CARISMA Therapeutics(納斯達克股票代碼:CARM)發起覆蓋,給予買入評級,並宣佈目標價爲$24。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。